Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Vitreous Body HELP
Based on 4,328 articles published since 2009

These are the 4328 published articles about Vitreous Body that originated from Worldwide during 2009-2019.
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Forming a Consensus: Data and Guidance for Physicians Treating Diabetic Macular Edema. 2016

Puliafito, Carmen A / Cousins, Scott W / Bacharach, Jason / Gonzalez, Victor H / Holekamp, Nancy M / Merrill, Pauline T / Ohr, Matthew P / Parrish, Richard K / Riemann, Christopher D. · ·Ophthalmic Surg Lasers Imaging Retina · Pubmed #27096289.

ABSTRACT: The diabetic macular edema (DME) treatment paradigm has evolved as the understanding of the disease pathology has grown. Since 2012, four pharmacotherapies have been approved by the U.S. Food and Drug Administration for the treatment of DME. First-line treatment of DME with anti-vascular endothelial growth factor [VEGF] agents has become the gold standard; however, an appreciable percentage of patients do not respond to anti-VEGF therapies. In patients who inadequately respond to anti-VEGF therapies, the underlying disease pathology may be mediated by a multitude of growth factors and inflammatory cytokines. For these patients, corticosteroids are an attractive treatment option because they not only downregulate VEGF, but also an array of cytokines. The phase 3 MEAD and FAME trials demonstrated significant visual acuity improvements associated with dexamethasone and fluocinolone acetonide, respectively, in patients with DME; however, class-specific adverse events, including increased intraocular pressure and cataract development, must be considered before use. A panel of experts gathered during the 2015 annual meeting of the American Academy of Ophthalmology for a roundtable discussion focused on patient selection and adverse event management associated with the use of the 0.19 mg fluocinolone acetonide intravitreal implant.

2 Guideline Idiopathic Epiretinal Membrane and Vitreomacular Traction Preferred Practice Pattern(®) Guidelines. 2016

Folk, James C / Adelman, Ron A / Flaxel, Christina J / Hyman, Leslie / Pulido, Jose S / Olsen, Timothy W. ·Department of Ophthalmology and Visual Sciences, University of Iowa Hospitals & Clinics, Iowa City, Iowa. · Department of Ophthalmology and Visual Science, Yale School of Medicine, New Haven, Connecticut. · Casey Eye Institute, Oregon Health & Science University, Portland, Oregon. · Division of Epidemiology, Department of Family, Population and Preventive Medicine, School of Medicine, Stony Brook University, Stony Brook, New York. · Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota. · Emory Eye Center, Emory University, Atlanta, Georgia. ·Ophthalmology · Pubmed #26578445.

ABSTRACT: GUIDELINES: New evidence-based Idiopathic Epiretinal Membrane and Vitreomacular Traction Preferred Practice Pattern® (PPP) guidelines, describing recommendations for the diagnosis, treatment, and management of patients.

3 Guideline Intravitreal injection technique and monitoring: updated guidelines of an expert panel. 2014

Avery, Robert L / Bakri, Sophie J / Blumenkranz, Mark S / Brucker, Alexander J / Cunningham, Emmett T / DʼAmico, Donald J / Dugel, Pravin U / Flynn, Harry W / Freund, K Bailey / Haller, Julia A / Jumper, J Michael / Liebmann, Jeffrey M / McCannel, Colin A / Mieler, William F / Ta, Christopher N / Williams, George A. ·*California Retina Consultants and Research Foundation, Santa Barbara, California; †Mayo Clinic, Rochester, Minnesota; ‡Byers Eye Institute, Stanford University School of Medicine, Stanford, California; §Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; ¶California Pacific Medical Center, San Francisco, California; **The Francis I. Proctor Foundation, UCSF School of Medicine, San Francisco, California; ††West Coast Retina, San Francisco, California; ‡‡Weill Cornell Medical College, New York-Presbyterian Medical Center, New York, New York; §§Keck School of Medicine, University of Southern California, Los Angeles, California; ¶¶Bascom Palmer Eye Institute, University of Miami, Miami, Florida; ***Vitreous-Retina-Macula Consultants of New York, New York; †††Wills Eye Hospital, Philadelphia, Pennsylvania; ‡‡‡Manhattan Eye, Ear & Throat Hospital, New York University Medical Center, New York, New York; §§§Jules Stein Eye Institute, University of California, Los Angeles, California; ¶¶¶University of Illinois, Chicago, Illinois; ****Stanford University School of Medicine, Stanford, California; and ††††Oakland University William Beaumont School of Medicine, Beaumont Eye Institute, Royal Oak, Michigan. ·Retina · Pubmed #25489719.

ABSTRACT: PURPOSE: To review evidence and provide updated guidelines on intravitreal (IVT) injection technique and monitoring. METHODS: A review of the published literature on IVT injection from 2004 to 2014 formed the basis for round table deliberations by an expert panel of ophthalmologists. RESULTS: The dramatic increase in the number of IVT injections has been accompanied by a comparable increase in evidence surrounding IVT practice patterns and techniques. The expert panel identified a number of areas that have evolved since publication of the original IVT injection guidelines in 2004, the most notable of which were a lack of evidence to support the routine use of pre-, peri-, and postinjection antibiotics to reduce the risk of endophthalmitis, and the role of aerosolized droplets containing oral contaminants from the patient and/or providers as a potential source of infection. The panel emphasized the continued importance of applying povidone-iodine to and avoiding eyelid contact with the intended injection site and needle. CONCLUSION: Updated guidelines on IVT injection technique and monitoring are proposed based on a review of published literature and expert panel deliberations.

4 Guideline [Guidelines of clinical practice of the SERV (Spanish Retina and Vitreous Society): management of ocular complications of diabetes. Diabetic retinopathy and macular oedema]. 2009

Pareja-Ríos, A / Serrano-García, M A / Marrero-Saavedra, M D / Abraldes-López, V M / Reyes-Rodríguez, M A / Cabrera-López, F / López-Gálvez, M / Cardona-Guerra, P / Abreu-Reyes, P / Quijada-Fumero, E / Coronado-Toural, A / Gutiérrez-Sánchez, E / Gil-Hernández, M A / Valls-Quintana, P / Marín-Olmos, F / Navarro-Alemany, R. ·Hospital Universitario de Canarias, La Laguna, Tenerife, España. aparejar@gmail.com ·Arch Soc Esp Oftalmol · Pubmed #19809923.

ABSTRACT: OBJECTIVE: Diabetes mellitus is considered the most common cause of blindness in the working population of industrialized countries, with diabetic macular edema being the most common cause of decreased visual acuity and proliferative diabetic retinopathy (PDR) being responsible for the most severe visual deficits. We have therefore tried to establish a guide for clinical intervention whose purpose is to provide orientation on the treatment of diabetic retinopathy and its complications. This is necessary at a time when many treatment options have emerged whose role is not yet fully defined. METHOD: A group of expert retina specialists selected by the SERV (Vitreous-Retina Spanish Society) assessed the published results of different treatment options currently available, suggesting lines of action according to the degree of diabetic retinopathy present and the presence or absence of macular edema. RESULTS: PDR is primarily treated with pan-retinal photocoagulation. For clinically significant diabetic macular edema without signs of vitreomacular traction, the treatment of choice continues to be focal/grid photocoagulation. Similarly, retinovitreal surgery is indicated for both conditions. The use of antiangiogenic drugs was also analyzed but remains inconclusive. CONCLUSION: Laser therapy is effective in the management of diabetic retinopathy and diabetic macular edema. The role of antiangiogenics is not yet sufficiently defined.

5 Editorial A perspective on the evolving field of vitreoretinal diseases. 2018

Sengupta, Sabyasachi. ·Future Vision Eye Care and Research Centre, Mumbai, India. ·Indian J Ophthalmol · Pubmed #30451161.


6 Editorial Posterior Vitreous Detachment. 2018

Sebag, J. · ·Ophthalmology · Pubmed #30143091.

ABSTRACT: -- No abstract --

7 Editorial Rheology and the Eye: blood, tears and other humours. 2018

Stefánsson, E / Snead, M P. ·University of Iceland, National University Hospital, Reykjavík, Iceland. · Vitreoretinal Service, Cambridge University NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK. ·Eye (Lond) · Pubmed #29417938.

ABSTRACT: -- No abstract --

8 Editorial Vascular endothelial growth factor inhibition for proliferative diabetic retinopathy: Et tu, Brute? 2017

Grauslund, Jakob. ·Department of Ophthalmology, Odense University Hospital, Odense, Denmark. · Department of Clinical Research, Faculty of Health Science, University of Southern Denmark, Odense, Denmark. ·Acta Ophthalmol · Pubmed #29220127.

ABSTRACT: -- No abstract --

9 Editorial Emerging Worldwide Antimicrobial Resistance, Antibiotic Stewardship and Alternative Intravitreal Agents for the Treatment of Endophthalmitis. 2017

Relhan, Nidhi / Pathengay, Avinash / Schwartz, Stephen G / Flynn, Harry W. ·*Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida †Retina and Uveitis Department, L V Prasad Eye Institute, GMR Varalakshmi Campus, Visakhapatnam, India. ·Retina · Pubmed #28338559.

ABSTRACT: -- No abstract --

10 Editorial Challenges with starting vitreoretinal services in the developing world. 2016

Amissah-Arthur, Kwesi Nyan. · ·Nepal J Ophthalmol · Pubmed #28242878.

ABSTRACT: Service development and improvement within ophthalmology has taken a whole new dimension with the constant improvement of equipment, and the development of therapies that significantly improve the management of our patients and as such alters their visual prognosis for the better. This improvement and increased reliance on both diagnostic and surgical equipment with the concomitant use of intravitreal therapies has arguably been felt more in the field of retinal diseases.

11 Editorial Vitreous: Not just through it. 2016

Sebag, Jerry. ·VMR Institute for Vitreous Macula Retina, Huntington Beach, California, USA. ·Clin Exp Ophthalmol · Pubmed #27758072.

ABSTRACT: -- No abstract --

12 Editorial Knowledge of vitreomacular traction (VMT) scenarios: Is doing nothing still a beneficial alternative and, if so, when? 2016

Ziemssen, Focke / Bartz-Schmidt, Karl Ulrich / Dimopoulos, Spyros. ·Centre for Ophthalmology, Eberhard-Karls-University, Schleichstr. 12, 72076, Tuebingen, Germany. focke.ziemssen@med.uni-tuebingen.de. · Centre for Ophthalmology, Eberhard-Karls-University, Schleichstr. 12, 72076, Tuebingen, Germany. ·Graefes Arch Clin Exp Ophthalmol · Pubmed #26887826.

ABSTRACT: -- No abstract --

13 Editorial Food and Drug Administration Procedures for New Drug and Device Approvals. 2016

Holland, Gary N / Eydelman, Malvina B / Cunningham, Brad / Chambers, Wiley A. ·Ocular Inflammatory Disease Center, UCLA Stein Eye Institute and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California. Electronic address: uveitis@jsei.ucla.edu. · Division of Ophthalmic and Ear, Nose, and Throat Devices, Office of Device Evaluation, Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, Maryland. · Division of Transplant & Ophthalmology Products, Office of Antimicrobial Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland. ·Am J Ophthalmol · Pubmed #26699740.

ABSTRACT: -- No abstract --

14 Editorial Mighty MyD88 in Health and Disease. 2016

Pulido, Jose S / Raja, Harish / Vile, Richard G / Salomao, Diva R / Viswanatha, David S. ·Departments of *Ophthalmology †Molecular Medicine and Immunology ‡Anatomic Pathology and §Hematopathology, Mayo Clinic, Rochester, Minnesota. ·Retina · Pubmed #26655610.

ABSTRACT: -- No abstract --

15 Editorial A Novel Issue for Vitreoretinal Surgeons. 2016

McClellan, Andrew J / Flynn, Harry W / Gayer, Steven. ·Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, Florida. ·Retina · Pubmed #26405768.

ABSTRACT: -- No abstract --

16 Editorial Vitreous in Age-Related Macular Degeneration Therapy--The Medium Is the Message. 2015

Sebag, J. ·VMR Institute for Vitreous Macula Retina, Huntington Beach, California. ·Retina · Pubmed #26312447.

ABSTRACT: -- No abstract --

17 Editorial Ocular Toxoplasmosis. 2015

Cunningham, Emmett T / Belfort, Rubens / Muccioli, Cristina / Arevalo, J Fernando / Zierhut, Manfred. ·Department of Ophthalmology, California Pacific Medical Center , San Francisco, California , USA . ·Ocul Immunol Inflamm · Pubmed #26066570.

ABSTRACT: -- No abstract --

18 Editorial Vitreous substitutes: from tamponade effect to intraocular inflammation. 2014

Romano, Mario R / Xu, Xun / Li, Kenneth K W. ·Department of Neuroscience, University Federico II, Via Pansini 5, 80131 Naples, Italy. · Department of Ophthalmology, Shanghai First People's Hospital Affiliated to Shanghai Jiaotong University, Shanghai, China. · Department of Ophthalmology, United Christian Hospital and Tseung Kwan O Hospital, Hong Kong ; Department of Ophthalmology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong. ·Biomed Res Int · Pubmed #25254203.

ABSTRACT: -- No abstract --

19 Editorial Intravitreal inflammation: from benchside to bedside 2013. 2014

Romano, Mario R / Christoforidis, John. ·Department of Ophthalmology, Humanitas Research Center, Rozzano, 20089 Milan, Italy ; Department of Neuroscience, University of Naples Federico II, 80131 Naples, Italy. · Department of Ophthalmology, College of Medicine, The University of Arizona, Tucson, AZ 85711, USA. ·Mediators Inflamm · Pubmed #24659859.

ABSTRACT: -- No abstract --

20 Editorial Safety and complications of ocriplasmin: ocriplasmin, ocriplasmin; oh, how safe art thou? 2014

Kim, Judy E. ·Department of Ophthalmology, The Eye Institute, Medical College of Wisconsin, Milwaukee. ·JAMA Ophthalmol · Pubmed #24577332.

ABSTRACT: -- No abstract --

21 Editorial Ocriplasmin: a medical or surgical therapy? 2013

Duker, Jay S / Moshfeghi, Andrew A. ·*New England Eye Center, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts †Retina Associates of Kentucky, Lexington, Kentucky. ·Retina · Pubmed #24113274.

ABSTRACT: -- No abstract --

22 Editorial Is the use of topical antibiotics for intravitreal injections the standard of care or are we better off without antibiotics? 2013

Chen, Royce W S / Rachitskaya, Aleksandra / Scott, Ingrid U / Flynn, Harry W. · ·JAMA Ophthalmol · Pubmed #23846201.

ABSTRACT: -- No abstract --

23 Editorial Intravitreal inflammation: from benchside to bedside. 2013

Romano, Mario R / Christoforidis, John / Abu El-Asrar, Ahmed M. · ·Mediators Inflamm · Pubmed #23401646.

ABSTRACT: -- No abstract --

24 Editorial How should we release vitreomacular traction: surgically, pharmacologically, or pneumatically? 2013

Johnson, Mark W. · ·Am J Ophthalmol · Pubmed #23312439.

ABSTRACT: -- No abstract --

25 Editorial Management of the dropped nuclear fragments. 2013

Karadag, Remzi / Aydin, Bahri. · ·Br J Ophthalmol · Pubmed #22942157.

ABSTRACT: -- No abstract --